在我的诊所给帕金森病患者的建议:益生菌和益生菌
Jia Wei Hor1, Tzi Shin Toh1, Shen-Yang Lim1
1Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Journal of Parkinson's disease
|August 30, 2024
概括
像益生菌这样的微生物疗法对帕金森病 (PD) 症状管理,特别是便秘有前途. 对于未来的治疗方法,需要对个性化微生物群干预措施进行进一步的研究.
科学领域:
- 微生物组研究的研究.
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
背景情况:
- 帕金森病 (PD) 越来越多地与肠道微生物组的改变有关.
- 基于微生物的疗法,包括益生菌和益生菌,正在成为PD的潜在治疗途径.
研究的目的:
- 审查目前对帕金森病中益生菌和益生菌的临床和临床前证据.
- 为临床医生提供指导,建议患者使用这些疗法.
- 确定未来的研究方向.
主要方法:
- 现有临床试验 (包括双盲安慰剂对照随机临床试验) 和临床前研究的综述.
- 对益生菌和益生菌在PD中的安全性和有效性的证据分析.
主要成果:
- 临床研究表明短期使用益生菌的安全性和有效性,主要用于改善PD患者的便秘.
- 临床前研究始终显示生物标志物,肠道功能障碍和神经保护的改善.
- 乳杆菌和Bifidobacterium是研究最多的益生菌属; 益生菌研究是有限的,重点是耐药粉和果性寡糖.
结论:
- 基于微生物的疗法,特别是益生菌,为管理某些帕金森病症状 (如便秘) 提供了一种安全且潜在的有效方法.
- 由宿主因素和宿主微生物群相互作用来决定的个性化微生物群干预,代表了PD治疗未来有希望的方向.
相关概念视频
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
328
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
328
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281


